Streetbeat News

ENVB

Enveric Biosciences, Inc.

https://www.enveric.com

Industry

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Open

0.48

Mkt cap

4.2M

Volume

501K

High

0.53

P/E Ratio

-0.14

52-wk high

2.92

Low

0.46

Div yield

N/A

52-wk low

0.36

Enveric Biosciences (NASDAQ:ENVB) reported a Q2 2024 GAAP EPS of $(0.23), significantly beating the analyst consensus estimate of $(0.55) by 58.18%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 9:39 pm

Merck & Co., Inc. (NYSE:MRK) shares fell 10% after the company reported second-quarter financial results and cut its FY24 adjusted EPS guidance below estimates. Despite beating revenue and EPS estimates, the guidance cut led to a sharp decline. Other stocks such as Imunon, Inc. (NASDAQ:IMNN) and JetBlue Airways Corporation (NASDAQ:JBLU) saw significant gains due to positive news, while QXO, Inc. (NASDAQ:QXO) and VBI Vaccines Inc. (NASDAQ:VBIV) experienced substantial losses.

Portfolio Pulse from Avi Kapoor

July 30, 2024 | 5:53 pm

F5, Inc. (NASDAQ:FFIV) shares surged over 14% in pre-market trading after reporting better-than-expected Q3 earnings and raising FY24 guidance. Other notable pre-market movers include Imunon, Inc. (NASDAQ:IMNN) up 104.2%, and Symbotic Inc. (NASDAQ:SYM) down 19.5% after disappointing earnings.

Portfolio Pulse from Avi Kapoor

July 30, 2024 | 9:50 am

Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results for its non-hallucinogenic psychedelic drug candidate EB-003, which can be administered orally. The company plans to advance EB-003 to clinical trials by the end of 2025. Enveric also recently obtained a US patent for another drug candidate, EB-002, aimed at treating neurological disorders.

Portfolio Pulse from Nina Zdinjak

July 25, 2024 | 12:00 pm

A coalition of prominent researchers has urged the FDA to approve MDMA-based therapy for PTSD, highlighting its proven safety and efficacy. This comes as the FDA is set to rule on Lykos Therapeutics' MDMA therapy by August 11. The paper emphasizes the urgent need for effective PTSD treatments, citing high suicide rates among U.S. military veterans.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 6:51 pm

Aries Science & Technology and Enveric Biosciences have announced a licensing agreement. Enveric Biosciences is eligible to receive milestone payments of up to $61 million on future sales if all conditions are met.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 12:12 pm

Enveric Biosciences (NASDAQ:ENVB) has announced that it is prioritizing the development of EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders without hallucinogenic effects. The company is advancing pre-clinical development and targeting a pre-IND meeting with the FDA for early 2025.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:03 pm

Oregon's pioneering psilocybin industry is struggling to attract customers a year after its launch. Despite the initial excitement, the industry faces challenges such as regulatory hurdles, marketing restrictions, and competition. Some service centers have already closed, and more may follow. Entrepreneurs and facilitators are working to raise awareness and adapt to the competitive market.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 6:07 pm

Enveric Biosciences has received a letter from Nasdaq notifying the company that it has regained compliance with the minimum stockholders' equity requirement.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 12:13 pm

Enveric Biosciences (NASDAQ:ENVB) reported a productive Q1 2024, reducing net loss and increasing cash on hand. The company advanced its lead drug candidate, EB-003, and executed seven non-binding out-license term sheets. Enveric's shares rose by 2.7919% to $0.81.

Portfolio Pulse from Jelena Martinovic

May 16, 2024 | 3:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.